Fundraising FoxNovo Holdings — 2025 Investments
11 investments dated 2025 · listed companies and verified rows first · show all
AMSilk produces biotech-derived silk protein yarns for textile applications including fashion, accessories, and automotive interiors, using fermentation-based bioprocessing instead of traditional sericulture.
Advanced ManufacturingBiotechCircular EconomyCleantechNew MaterialsMunich, DE
Co-investorsAthosMIG Capital AG
Extracellular is a biomanufacturing company that helps cell-based product developers in cultivated meat, plant cell culture, and bioactives accelerate discovery, overcome production challenges, and commercialize their products.
Advanced ManufacturingBiotechFoodTechNew Materials
Will Milligan(CEO & Founder)in
Co-investorsBig Idea VenturesFFFNewland SyndicateUnruly Capital5AM VenturesAgent Capital+8 more
GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs.
BiotechHealthtechNewton, US
Ganesh V. Kaundinya(President & CEO)in
Co-investors5AM VenturesCatalio Capital Management, LPLifeArc VenturesRoche Venture FundSixty Degree CapitalSofinnova Partners+1 more
BiotechBoston, US
David Donabedian(Executive Officer, Director)inRobert Hadfield(Executive Officer)inJohn McCabe(Executive Officer)in
BoardChristoph Westphal(Director)Ming Cheah(Director)inRaymond Camahort(Director)
Co-investorsDCVC (Data Collective)DCVC BioArkin CapitalLongwood Fund
Orbis Medicines is a drug discovery company developing orally bioavailable macrocycle drug candidates as alternatives to injectable biologics, targeting both intracellular and extracellular protein targets.
AI & Machine LearningBiotechDeep Tech
Co-investorsNew Enterprise Associates (NEA)ForbionLilly Ventures
Phasecraft develops quantum computing systems and software by combining quantum information theory, materials science, and engineering to advance practical quantum advantage.
AI & Machine LearningDeep TechQuantum Computing
Prof. Ashley Montanaro(Co-Founder & CEO)inProf. Toby Cubitt(Co-Founder, CTO & CSciO)inProf. John Morton(Co-Founder & Director)inAshley Montanaro(Founder)John Morton(Founder)Toby Cubitt(Founder)
Co-investorsAlbionVCEpisode1LocalGlobePlayground GlobalUCL Technology FundLatitude+3 more
Reunion Neuroscience is a clinical-stage biopharmaceutical company developing serotonergic psychedelic therapies for mental health conditions such as postpartum depression, adjustment disorder, and generalized anxiety disorder.
BiotechDigital HealthMental HealthMorristown, US
Sahil V. Kirpekar(President and CEO)inGregory Mayes(Executive Officer, Director)Ellen Lubman(Director)Mark Pollack(Executive Officer)inNathan Bryson(Executive Officer)inMark Theeuwes(Executive Officer)in
Co-investorsFemHealth VenturesMitsui Global InvestmentMPM BioImpactPalo Santo VC
Sparrow Quantum develops quantum computing technology, building on research from the Niels Bohr Institute in Copenhagen where the company originated.
Deep TechHardwareQuantum ComputingCopenhagen, DK
Peter Lodahl(Founder)
Co-investorsLIFTTScale Capital2xNBalderton CapitalEuropean Investment Bank
Supira Medical develops a next-generation percutaneous ventricular assist device (pVAD) to provide temporary mechanical circulatory support for high-risk patients undergoing coronary interventions and those in cardiogenic shock.
HardwareHealthtechMedical DevicesCampbell, US
Nitin Salunke(President & CEO)inJean Orth(Executive Officer)Mariam Maghribi(Executive Officer, Director)
BoardCasey Gordon(Director)Christopher Shen(Director)Bihua Chen(Director)
Co-investors415 CapitalAmed VenturesThe Capital PartnershipUnorthodox VenturesQatar Investment Authority
The Protein Brewery develops FERMOTEIN, a fermentation-based whole food ingredient made from fungal mycelium that provides complete protein and prebiotic fiber.
BiotechFoodTechBreda, NL
Thijs Bosch(CEO)in
Co-investorsBOMUnovis Asset ManagementInvest-NL
Tribune Therapeutics is a preclinical biopharmaceutical company developing medicines that target CCN protein family signaling (such as CCN2/CTGF) to block fibrotic pathways.
BiotechHealthtech
Ole Kaasbøll(Co-founder)
Co-investorsHealthCapIndustrifondenInnovestor VenturesLifeArc VenturesInvestinor
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.